Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of phase I and phase II drug metabolism.

Current pharmaceutical design - 1 Jan 2010

Crettol Severine, Petrovic Nenad, Murray Michael

Abstract excerpt

Genetic variation in the receptors and other intracellular targets that mediate the pharmacodynamic effects of drugs can affect therapeutic outcomes. However, at present greater knowledge is available concerning the extent of gene variation in drug metabolizing enzymes that determine drug pharmacokinetics and, in turn, drug efficacy and toxicity. Information on the incidence of polymorphisms in the cytochrome...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biotransformation
Share to NAT2 gene
Share to Pharmacogenetics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pharmacokinetics

Share to Polymorphism, Single Nucleotide

Source

Identifiers

PMID: 19835560
DOI: 10.2174/138161210790112674

Genes

NAT2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of phase I and phase II drug metabolism.PMID 19835560Read ↗

Genetic basis of drug metabolism.Semantic proximity Read ↗

Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of anticancer agents.Semantic proximity Read ↗

Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevanceSemantic proximity Read ↗

Cytochromes P450: decision-making tools for personalized therapeutics.Semantic proximity Read ↗

Pharmacogenetic Variation in Drug Oxidizing CYPs: Impact on Drug Therapy, Drug Safety and Drug Interactions.Semantic proximity Read ↗

Drug Metabolizing Enzymes: An Exclusive Guide into Latest Research in Pharmaco-genetic Dynamics in Arab CountriesSemantic proximity Read ↗

[Individualization of drug therapy and pharmacogenetics].Semantic proximity Read ↗

[Xenobiotic-metabolizing polymorphic enzymes. An opportunity for individualized drug treatment].Semantic proximity Read ↗

Allelic expression of phase II metabolizing enzymes and relationship to irinotecan toxicity.Semantic proximity Read ↗

The human cytochrome P450 Allele Nomenclature Committee Web site: submission criteria, procedures, and objectives.Semantic proximity Read ↗

Cytochrome P450 in Pharmacogenetics: An Update.Semantic proximity Read ↗

Clinically relevant genetic variations in drug metabolizing enzymes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.